About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

339,504 studies
in
214 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 06/01/2020.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 06/01/2020.
Our Science
  • Lisocabtagene maraleucel (liso-cel; JCAR017; Anti-CD19 CAR T Cells)

    The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

    Proposed Mechanism of Action

    Liso-cel is an investigational chimeric antigen receptor (CAR) T cell therapy designed to target CD19,1,2 which is a surface glycoprotein expressed during normal B-cell development and maintained following malignant transformation of B cells.3-5 Liso-cel CAR T cells aim to target and CD-19 expressing cells through a CAR construct that includes an anti-CD19 single-chain variable fragment (scFv) targeting domain for antigen specificity, a transmembrane domain, a 4-1BB costimulatory domain hypothesized to increase T-cell proliferation and persistence, and a CD3-zeta T-cell activation domain.1,2,6-9 The controlled manufacturing process for liso-cel results in a defined composition therapy consisting of CD8+ and CD4+ CAR T cells; however, the clinical significance of defined composition is unknown.1,10

    Liso-cel Proposed Mechanism of Action

    Lisocabtagene maraleucel (liso-cel; JCAR017) by Disease State

    Lisocabtagene maraleucel (liso-cel; JCAR017) in Lymphoma

    Phase 3
    Aggressive large B-cell lymphoma: Relapsed/refractory

    View Trials Investigating Lisocabtagene maraleucel (liso-cel; JCAR017) in Lymphoma
    View Rationale for Clinical Development

    Rationale for Clinical Development

    Preclinical studies have suggested that CAR T cells directed against CD19 demonstrate antitumor activity against lymphoma cells in mouse models.11,12

    Lisocabtagene maraleucel (liso-cel; JCAR017) in Chronic Lymphocytic Leukemia

    Phase 2
    CLL

    View Trials Investigating Lisocabtagene maraleucel (liso-cel; JCAR017) in Chronic Lymphocytic Leukemia
    View Rationale for Clinical Development

    Rationale for Clinical Development

    Preclinical studies have demonstrated cytolytic activity of anti-CD19 CAR T cells co-cultured with K562 CD19+ tumor cells as well as antitumor activity of anti-CD19 CAR T cells in several mouse models of CLL.13

    View Related Pathways

    References

    1. Abramson AS, et al. Oral presented at ASH 2017 [abstract 581].
    2. NCI Drug Dictionary. https://www.cancer.gov/publications/dictionaries/cancer-drug/def/778386. Accessed November 18, 2019.
    3. Scheuermann RH, Racila E. Leuk Lymphoma. 1995;18:385-397. PMID: 8528044
    4. Wang K, et al. Exp Hematol Oncol. 2012;1:36. PMID: 23210908
    5. Maude SL, et al. Blood. 2015;125:4017-4023. PMID: 25999455
    6. Dotti G, et al. Immunol Rev. 2014;257:107-126. PMID: 24329793
    7. Bridgeman JS, et al. Clin Exp Immunol. 2014;175:258-267. PMID: 24116999
    8. Davila ML, et al. Int J Hematol. 2014;99:361-371. PMID: 24311149
    9. Maus MV and June CH. Clin Cancer Res. 2016;22:1875-1884. PMID: 27084741
    10. Ramsborg CG, et al. Poster presentation at ASH 2017 [abstract 4471].
    11. Cheadle EJ, et al. J Immunol. 2010;184:1885-1896. PMID: 20089697
    12. Kochenderfer JN, et al. Blood. 2010;116:3875-3886. PMID: 20631379
    13. Qin J, et al. Blood. 2016;128:3231.